Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Inolimomab for primary steroid-resistant acute graft versus host disease after allogeneic stem cell transplantation
2006-005019-81Phase 2Completed
- Sponsor
- OPi
- Start
- Nov 2006
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of inolimomab in graft-versus-host disease (GVHD), sponsored by OPi. Primary endpoint: Overall response rate at day 29. Started Nov 2006; status: completed.
02
Drugs
inolimomab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on 2006-005019-81.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2006-005019-81.